February 15, 2023:

Sara E. Fenton, MD, PhD of Northwestern University will present a Big Ten Cancer Research Consortium prostate cancer study during the American Society of Clinical Oncology Genitourinary (GU) Cancers Symposium on February 16-18, 2023, in San Francisco, CA.

Additionally, the Big Ten CRC GU clinical trial working group will meet in-person during the conference on Thursday, February 16th at 6 AM PT / 8 AM CT / 9 AM ET. Call in information is available for investigators to join virtually.

This abstract titled “A phase I trial of androgen deprivation, darolutamide, and ipatasertib in a safety cohort with castration-resistant prostate cancer (ADDITION)” will be featured during Poster Session A: Prostate Cancer in the Prostate cancer-advanced, prostate cancer-localized track (subtract therapeutics) on February 16 at 11:30 AM PT.

Abstract # 174 | Poster #F11

BTCRC-GU19-404 is a single arm, phase I/II trial of neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men with localized, high risk prostate cancer led by David VanderWeele, MD at Northwestern University.

The goal of the study was to estimate the efficacy of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with previously untreated, localized, high-risk prostate cancer that is lacking PTEN, as measured by the pathological complete response or minimal residual disease. The PTEN gene provides instructions for making an enzyme that is found in almost all tissues in the body. 

In this abstract, investigators found that combination therapy with darolutamide and ipatasertib in castration resistant prostate cancer is safe and a recommended phase 2 dose of ipatasertib was established.

Participating institutions include Northwestern University and Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Authors include Sarah Elizabeth Fenton, Rachel Springsdorf, Siobhan Kenny, Ashley Ross, Masha Kocherginsky, Maha H. A. Hussain, David James VanderWeele, Lauren Bere.